Stella Pharma Statistics
Total Valuation
Stella Pharma has a market cap or net worth of JPY 11.63 billion. The enterprise value is 9.55 billion.
| Market Cap | 11.63B |
| Enterprise Value | 9.55B |
Important Dates
The last earnings date was Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Stella Pharma has 35.03 million shares outstanding. The number of shares has increased by 1.93% in one year.
| Current Share Class | 35.03M |
| Shares Outstanding | 35.03M |
| Shares Change (YoY) | +1.93% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 4.11% |
| Owned by Institutions (%) | 1.23% |
| Float | 21.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.01 |
| PB Ratio | 4.79 |
| P/TBV Ratio | 4.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.25 |
| EV / Sales | 29.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -27.69 |
Financial Position
The company has a current ratio of 16.81, with a Debt / Equity ratio of 0.31.
| Current Ratio | 16.81 |
| Quick Ratio | 11.16 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.16 |
| Interest Coverage | -107.00 |
Financial Efficiency
Return on equity (ROE) is -27.69% and return on invested capital (ROIC) is -13.10%.
| Return on Equity (ROE) | -27.69% |
| Return on Assets (ROA) | -9.45% |
| Return on Invested Capital (ROIC) | -13.10% |
| Return on Capital Employed (ROCE) | -17.72% |
| Weighted Average Cost of Capital (WACC) | 5.41% |
| Revenue Per Employee | 7.51M |
| Profits Per Employee | -18.14M |
| Employee Count | 43 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.03 |
Taxes
In the past 12 months, Stella Pharma has paid 2.00 million in taxes.
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.32% in the last 52 weeks. The beta is 0.27, so Stella Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -13.32% |
| 50-Day Moving Average | 576.72 |
| 200-Day Moving Average | 394.27 |
| Relative Strength Index (RSI) | 27.04 |
| Average Volume (20 Days) | 831,585 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Stella Pharma had revenue of JPY 323.00 million and -780.00 million in losses. Loss per share was -22.93.
| Revenue | 323.00M |
| Gross Profit | 279.00M |
| Operating Income | -749.00M |
| Pretax Income | -778.00M |
| Net Income | -780.00M |
| EBITDA | -721.00M |
| EBIT | -749.00M |
| Loss Per Share | -22.93 |
Balance Sheet
The company has 2.82 billion in cash and 746.00 million in debt, with a net cash position of 2.08 billion or 59.29 per share.
| Cash & Cash Equivalents | 2.82B |
| Total Debt | 746.00M |
| Net Cash | 2.08B |
| Net Cash Per Share | 59.29 |
| Equity (Book Value) | 2.43B |
| Book Value Per Share | 71.31 |
| Working Capital | 4.09B |
Cash Flow
In the last 12 months, operating cash flow was -334.00 million and capital expenditures -11.00 million, giving a free cash flow of -345.00 million.
| Operating Cash Flow | -334.00M |
| Capital Expenditures | -11.00M |
| Depreciation & Amortization | 28.00M |
| Net Borrowing | -19.00M |
| Free Cash Flow | -345.00M |
| FCF Per Share | -9.85 |
Margins
Gross margin is 86.38%, with operating and profit margins of -231.89% and -241.49%.
| Gross Margin | 86.38% |
| Operating Margin | -231.89% |
| Pretax Margin | -240.87% |
| Profit Margin | -241.49% |
| EBITDA Margin | -223.22% |
| EBIT Margin | -231.89% |
| FCF Margin | n/a |
Dividends & Yields
Stella Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.93% |
| Shareholder Yield | -1.93% |
| Earnings Yield | -6.71% |
| FCF Yield | -2.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Stella Pharma has an Altman Z-Score of 3.95 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.95 |
| Piotroski F-Score | 3 |